What is the typical Pemvidutide dosage?

Published protocols describe 1.2–2.4 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of Pemvidutide?

Risks noted for Pemvidutide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.

What is the half-life of Pemvidutide?

The reported half-life is ~5–6 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.

How should Pemvidutide be stored?

Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

GLP-1 · PEPTIDE

What is Pemvidutide?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

Pemvidutide is an investigational once-weekly injectable that activates the GLP-1 and glucagon receptors in a balanced one-to-one ratio. It is being studied for obesity and MASH.

Pemvidutide at a glance

Type: Peptide
Also known as: ALT-801
Mechanism: Balanced GLP-1 / glucagon dual agonist
Status: Phase 2
Half-life: ~5–6 days (limited data)
Route: Subcutaneous
Dosing range in the literature: 1.2–2.4 mg weekly
Onset: 2–4 weeks for appetite reduction
Storage: Refrigerated (2–8 °C); use within the pharmacy beyond-use date

How Pemvidutide works

The GLP-1 component reduces appetite and the glucagon component is thought to increase energy expenditure and reduce liver fat. Trials have also looked at how much of the weight lost is fat versus lean mass.

What Pemvidutide is studied for

Weight management
Liver fat reduction
Lean-mass preservation

Phase 2 trials reported weight loss of around 15% at 48 weeks at the highest dose, with reductions in liver fat. Larger trials are needed to confirm this.

Being studied for something is not proof that it works. Results in individuals vary.

Pemvidutide dosing

Published protocols describe 1.2–2.4 mg weekly, once weekly, given subcutaneous. Onset is typically reported at 2–4 weeks for appetite reduction.

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

Pemvidutide dosage calculator →

Pemvidutide side effects and risks

Nausea
Vomiting
Diarrhea
Constipation

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is Pemvidutide FDA approved?

Investigational. In phase 2 trials and not approved by the FDA.

Approval and trial status change. This page was last reviewed on October 1, 2026.

Pemvidutide at G1 Peptides

G1 Peptides does not currently supply Pemvidutide. A provider can discuss alternatives in a free consultation.

Pemvidutide questions

What is Pemvidutide?: Pemvidutide is an investigational once-weekly injectable that activates the GLP-1 and glucagon receptors in a balanced one-to-one ratio. It is being studied for obesity and MASH.
What is Pemvidutide used for?: Pemvidutide is studied for weight management, liver fat reduction, and lean-mass preservation. Phase 2 trials reported weight loss of around 15% at 48 weeks at the highest dose, with reductions in liver fat. Larger trials are needed to confirm this.
How does Pemvidutide work?: The GLP-1 component reduces appetite and the glucagon component is thought to increase energy expenditure and reduce liver fat. Trials have also looked at how much of the weight lost is fat versus lean mass.
Is Pemvidutide FDA approved?: Investigational. In phase 2 trials and not approved by the FDA.
What is the typical Pemvidutide dosage?: Published protocols describe 1.2–2.4 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of Pemvidutide?: Risks noted for Pemvidutide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.
What is the half-life of Pemvidutide?: The reported half-life is ~5–6 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.
How should Pemvidutide be stored?: Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.